Genentech’s Atezolizumab for Advanced Non-small Cell Lung Cancer Granted FDA Priority Review
News
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Biologics License Application (BLA) and granted Priority Review status for atezolizumab for patients with locally advanced or metastatic non-small cell ... Read more